Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

2014327 citationsJournal Articlebronze Open Access

Authors

www.clinicaltrials.gov (NCT01328041) and http://www.gsk-clinicalstudywww.gsk-clinicalstudyregister.com (112574).

Good health and well-being

Published in: The Journal of Infectious Diseases

Volume 210, Issue 3, pp. 354-362

Field-Weighted Citation Impact: 22.85